An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

NCT00924092 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Prostate Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Head and Neck Cancer

Interventions

BIOLOGICAL: GI-6207 [Recombinant Saccharomyces Cerevisia
DRUG: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])

Sponsor

National Cancer Institute (NCI)